Brief: Eloxx Pharmaceuticals Says Enrollment In Phase 2 Clinical Trial In Cystic Fibrosis Has Resumed In Israel And Europe
17/06/2020 22:19
June 17 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ENROLLMENT IN PHASE 2 CLINICAL TRIAL IN CYSTIC FIBROSIS
HAS BEEN
RESUMED IN ISRAEL AND EUROPE AFTER BEING PAUSED TEMPORARILY IN
RESPONSE TO THE COVID-19 PANDEMIC
* ELOXX PHARMACEUTICALS INC - U.S. TRIAL REMAINS TEMPORARILY
PAUSED DUE TO COVID-19 PANDEMIC
Source text for Eikon: ID:nGNX3ynMvk
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome